Technology
Health
Pharmaceutical

Evelo Biosciences

$7.48
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.22 (-2.86%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell EVLO and other stocks, options, ETFs, and crypto commission-free!

About

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines. Its product candidates are single strains of microbes, selected for defined pharmacological properties. Read More The firm currently has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.

Employees
75
Headquarters
Cambridge, Massachusetts
Founded
2014
Market Cap
239.59M
Price-Earnings Ratio
Dividend Yield
Average Volume
60.42K
High Today
$7.65
Low Today
$7.42
Open Price
$7.65
Volume
10.34K
52 Week High
$16.75
52 Week Low
$6.51

Collections

Technology
Health
Pharmaceutical
Medical
Biotechnology
Cancer Prevention
2018 IPO
US

News

The Motley FoolMay 4

Evelo Biosciences, Inc. (EVLO) Q1 2019 Earnings Call Transcript

Evelo Biosciences, Inc. (NASDAQ:EVLO) Q1 2019 Earnings Call , 8:30 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good morning, and welcome to the Evelo first-quarter 2019 financial results conference Call. [Operator instructions] Please be advised that this call is being recorded at the company's request. At this time, I'd like to turn the call over to Stefan Riley of Evelo. Please proceed. Stefan Riley -- Investor Relations Thank you, opera...

14
Yahoo FinanceMay 2

Evelo Biosciences Reports First Quarter 2019 Financial Results and Recent Business Highlights

-- Novel Formulation of Monoclonal Microbials Discovered, Preclinical Potency Increased by up to 30-Fold: Plan to Introduce New Formulation into Ongoing Clinical Trials in Second Half of 2019 -- -- Initial Clinical Data for EDP1066 Expected Early in Third Quarter of 2019 -- -- On Track to Deliver 10 Clinical Readouts Across 2019 and 2020 -- CAMBRIDGE, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (EVLO) ("Evelo"), a clinical stage biotechnology company developing oral biologics that ac...

10

Earnings

-$3.29
-$2.31
-$1.34
-$0.36
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.53 per share
Actual
-$0.64 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.